YOLFTbeta
Crescent Biopharma, Inc.

Crescent Biopharma, Inc.

CBIO · NASDAQ · Healthcare / Biotechnology

14.15USD-0.22 (-1.53%)

Price History

Full chart

Market Stats

Previous Close14.37
Open15.21
Day Range13.53 – 15.21
52-Week Range8.72 – 27.41
Volume284.75K
Market Cap528.97M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.14
Dividend Yield0.00%
50-Day Avg17.02
200-Day Avg15.72

About

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Joshua T. Brumm
  • Employees69
  • Headquarters300 Fifth Avenue, Waltham, MA, United States, 02451, USA
  • Websitehttps://crescentbiopharma.com

Leadership

  • Mr. Joshua T. BrummCEO & Director · b. 1978
  • Dr. Jonathan McNeill M.D.President & COO · b. 1985
  • Dr. Ellie Im M.D.Chief Medical Officer · b. 1978
  • Mr. Richard William Scalzo M.B.A.Chief Financial Officer · b. 1986
  • Mr. Ryan LynchSenior VP of Finance, Treasurer & Chief Accounting Officer · b. 1984
  • Dr. Wenjie Cheng Ph.D.Senior Vice President of Technical Operations
  • Dr. Jan Pinkas Ph.D.Chief Scientific Officer · b. 1969
  • Ms. Barbara Bispham Hale J.D.General Counsel & Corporate Secretary · b. 1987
  • Ms. Amy ReillyChief Communications Officer · b. 1974
  • Mr. Christopher DoughtyChief Business Officer · b. 1988

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.81M15.26M3.99M15.03M20.07M18.50K---10.16M1.16M75.00K10.00K-10.84M
Growth (%)-+300.04%-73.83%+276.37%+33.56%-99.91%-----88.59%-93.53%-86.67%--
Cost of Revenue83.86K-----263.54K275.12K899.30K951.60K-1.03M153.30K35.17K84.00K
Gross Profit3.73M15.26M3.99M15.03M20.07M18.50K-263.54K-275.12K-899.30K10.16M1.16M75.00K10.00K-35.17K10.84M
Gross Margin97.80%100.00%100.00%100.00%100.00%100.00%---100.00%100.00%100.00%100.00%-100.00%
Operating Expense9.81M11.62M14.60M26.17M32.86M31.93M33.67M51.23M60.49M61.67M64.61M47.48M39.29M49.86M163.48M
Operating Income-6.08M3.64M-10.61M-11.14M-12.78M-31.91M-33.93M-51.51M-61.39M-51.51M-63.45M-47.40M-39.28M-49.90M-152.63M
Operating Margin-159.54%23.82%-265.65%-74.13%-63.70%-172505.32%----506.84%-5470.69%-63204.43%-392752.93%--1407.52%
EBITDA-6.00M3.73M-10.47M-10.98M-12.59M-31.72M-33.67M-51.23M-56.99M-51.24M-63.18M-47.20M-39.12M-44.17M-149.67M
EBITDA Margin-157.34%24.48%-262.34%-73.08%-62.74%-171475.38%----504.17%-5447.87%-62927.65%-391213.55%--1380.24%
Net Income-6.11M3.66M-10.61M-11.12M-12.77M-31.81M-33.28M-48.27M-54.12M-51.03M-63.43M-46.69M-36.90M-48.52M-153.94M
Net Income Margin-160.29%23.96%-265.63%-74.01%-63.62%-171945.07%----502.09%-5468.98%-62251.74%-368994.20%--1419.61%
R&D7.80M9.44M11.70M19.57M25.05M23.28M24.10M40.09M47.03M44.93M47.49M28.39M20.07M28.06M138.09M
R&D as % of Total Revenue204.49%61.86%293.07%130.24%124.81%125847.68%---442.09%4094.92%37854.51%200716.56%-1273.39%
Interest Expense-------------852.00K2.19M
Interest Expense % of Total Revenue--------------20.15%

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets28.91M18.42M5.28M57.26M48.46M42.39M128.58M214.84M167.97M142.83M94.35M51.81M45.32M35.62M240.29M
Total Liabilities20.45M5.89M2.38M6.46M7.99M7.09M8.88M9.38M13.77M14.61M12.74M8.88M6.90M51.10M37.28M
Total Equity8.46M12.53M2.91M50.80M40.47M35.30M119.70M205.46M154.20M128.22M81.60M42.93M38.41M-15.48M203.01M
Cash28.17M17.37M2.31M55.20M46.80M40.04M123.92M209.92M158.20M137.04M90.25M47.87M41.79M34.77M213.19M
Total Debt--------3.62M2.82M1.92M918.55K808.40K37.48M1.64M
Net Debt-28.17M-17.37M-2.31M-55.20M-46.80M-40.04M-123.92M-209.92M-154.58M-134.22M-88.33M-46.95M-40.98M2.72M-211.55M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow13.85M-10.47M-15.54M-4.28M-8.24M-29.73M-29.77M-43.33M-51.98M-39.24M-57.49M-46.46M-34.88M-31.10M-71.53M
Investing Cash Flow-240.14K-326.18K-82.09K-212.60K-268.59K-704.20K-294.11K-125.62K-144.93K-68.51K-14.94K-84.19K-21.39K20.03K-72.92M
Financing Cash Flow-24.16K237558.93K57.38M114.12K23.67M113.95M129.45M412.91K18.14M10.72M4.16M28.82M5.40K322.98M
Capital Expenditure182.44K316.18K82.09K212.60K268.59K704.20K294.11K125.62K144.93K68.51K14.94K84.19K21.39K9.97K72.92M
Free Cash Flow13.67M-10.79M-15.62M-4.49M-8.51M-30.44M-30.06M-43.46M-52.13M-39.31M-57.50M-46.54M-34.90M-31.11M-144.45M
FCF to OCF98.68%103.02%100.53%104.97%103.26%102.37%100.99%100.29%100.28%100.17%100.03%100.18%100.06%100.03%201.94%

Earnings

Report DateMay 8, 2014Aug 1, 2014Oct 31, 2014Mar 17, 2015May 6, 2015Jul 31, 2015Nov 12, 2015Feb 29, 2016May 4, 2016Aug 5, 2016Nov 4, 2016Mar 1, 2017May 3, 2017Aug 3, 2017Nov 8, 2017Mar 6, 2018May 3, 2018Aug 9, 2018Nov 2, 2018Mar 6, 2019May 2, 2019Aug 1, 2019Nov 7, 2019Feb 28, 2020May 1, 2020Jul 31, 2020Nov 6, 2020Mar 2, 2021May 3, 2021Aug 5, 2021Nov 2, 2021Mar 3, 2022Apr 28, 2022Aug 3, 2022Nov 9, 2022Mar 29, 2023May 3, 2023Aug 2, 2023Nov 3, 2023Mar 27, 2024May 10, 2024Aug 1, 2024Nov 29, 2024Feb 27, 2025Jun 18, 2025Jul 31, 2025Nov 6, 2025Feb 26, 2026Apr 30, 2026Jul 30, 2026Nov 5, 2026
EPS Estimate-----------0.44-0.35-0.37-0.37-0.28-0.26-0.28-0.33-0.30-0.30-0.34-0.37-0.31-0.34-0.18-0.32-0.29-0.32-0.28-0.28-0.34-0.33-0.28-0.25-0.25-0.17-0.16-0.18-0.14-0.15-0.17-0.16-0.11-0.09-3.64-3.68-1.38-2.22-0.79-0.78-0.72
EPS Actual-27.1639.49-35.03-39.12-37.4951.34-37.68-46.64-39.61-40.78-0.34-0.36-0.34-0.30-0.24-0.27-0.33-0.26-0.27-0.32-0.33-0.37-0.31-0.34-0.18-0.32-0.29-0.32-0.28-0.28-0.34-0.33-0.28-0.25-0.16-0.19-0.17-0.13-0.14-0.14-0.17-0.15-15.24-0.08-18.39-3.72-1.37-4.01-0.70-0.74-
Surprise----------22.73%-2.86%8.11%18.92%14.29%-3.85%-17.86%21.21%10.00%-6.67%2.94%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%36.00%-11.76%-6.25%27.78%0.00%6.67%0.00%3.13%-13750.27%11.11%-405.22%-1.09%0.72%-80.63%11.02%5.13%-
Timing--------------------------------------------After-hoursPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap528.97M
Enterprise Value360.96M
Trailing P/E0.00
Forward P/E0.00
Price / Sales44.51
Price / Book3.31
EPS-0.14
Book Value4.77
Revenue (TTM)11.88M
Gross Profit (TTM)11.88M
EBITDA-170.03M
Profit Margin0.00%
Operating Margin-1432.64%
Return on Equity-160.75%
Return on Assets-69.15%
Shares Outstanding37.14M
Shares Float26.65M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
82.88%
Insiders
0.27%
Retail / Other
16.85%

Top Institutional Holders

  • FMR Inc
    4.13M11.13%
  • Bvf Inc
    2.75M7.40%
  • Fairmount Funds Management LLC
    2.75M7.40%
  • VR Adviser, LLC
    2.13M5.74%
  • Logos Global Management LP
    1.90M5.11%
  • FCPM III SERVICES BV
    1.68M4.52%
  • Balyasny Asset Management LLC
    1.51M4.07%
  • Vestal Point Capital LP
    1.50M4.04%
  • Opaleye Management Inc
    1.32M3.55%
  • TANG CAPITAL MANAGEMENT LLC
    1.16M3.12%
  • Vanguard Capital Management, LLC
    801.39K2.16%
  • Boxer Capital Management, LLC
    453.69K1.22%
  • Millennium Management LLC
    403.86K1.09%
  • Jennison Associates LLC
    378.51K1.02%
  • NEXTBio Capital Management LP
    372.86K1.00%
  • RTW INVESTMENTS, LLC
    372.86K1.00%
  • Remedium Capital Partners, LLC
    361.25K0.97%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    906.65K2.44%
  • iShares Russell 2000 ETF
    532.28K1.43%
  • Fidelity Small Cap Growth
    518.53K1.40%

Dividends

20231×
24.00Jan 13, 2023
20221×
143.00Sep 21, 2022

Stock Splits

  • Jun 16, 20251:100